Skip to main navigation Skip to search Skip to main content

Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer

  • Sridha Ganesh
  • , Rui Wang
  • , Honglei Chen*
  • *Corresponding author for this work

Research output: Contribution to journal › Review › peer-review

3 Scopus citations

Abstract

Non-small cell lung cancer (NSCLC) constitutes about 84% of lung cancer. Hence, increased efforts have been fueled into immunotherapy of NSCLC with immune checkpoint inhibitors (ICIs). ICIs have recently taken off as promising immune-therapeutic methods that have slowed down the progress of NSCLC and equipped patients with survival advantages. However, the long-term respondents tally is less than 20% of the population. This low response rate warrants the need for dynamic biomarkers which will provide insight into the possible response of patients to ICIs. Biomarkers are biological molecules that predict the pathologic state of patients and the potential response they will elicit to ICIs. Predictive biomarkers play a crucial role in analyzing the effects of ICI therapy on patients and potentially filter out patients who will certainly benefit from ICIs. In this way, resources in immunotherapy can be rationalised better and the healthcare system can administer an alternative mode of treatment to the non-responsive group of patients. Thus, precision therapy can be performed according to the possible responsiveness and needs of patients. PD-L1 protein is a popular biomarker that has been analyzed extensively to study the immunotherapy effectiveness of PD-L1 and PD-1 inhibitors. But as a single biomarker, PD-L1 protein levels do have their shortcomings to check for ICI therapy effectiveness. As such, this emphasizes the need for exploration of more biomarkers to be used on prediction grounds. A combination of biomarkers may also be considered for better prediction results. This review serves to highlight the importance of PD-L1 protein in dynamic monitoring of the immunotherapy effectiveness and investigates different novel biomarkers that could be plausible options to monitor immunotherapy effectiveness of NSCLC.
Original languageEnglish
Pages (from-to)335-350
Number of pages16
JournalOncologie
Volume23
Issue number3
DOIs
StatePublished - Jan 2021

Funding

This work was partly supported by the National Natural Science Foundation of China (No. 81872443).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Immunotherapy
  • immune checkpoint inhibitors
  • dynamic monitoring
  • lung cancer

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this